Home » Newsletters » BioWorld Science

BioWorld Science

April 4, 2017

View Archived Issues

Astellas set to acquire Ogeda

CSL Behring's Kcentra approved in Japan

T-CiRA partnership joins RIKEN to discover drug for NGLY1 deficiency

Novel cellular model of anorexia nervosa reported

Arnuity Ellipta approved in Japan for bronchial asthma

Samus Therapeutics announces expanded clinical development for epichaperome platform

Genentech presents new bicyclic-proline TRPA1 antagonists with improved physical properties

GlaxoSmithKline identifies novel PERK inhibitors

Taiho Pharmaceutical discovers new proto-oncogene RET inhibitors

INSERM and collaborators divulge novel GPBAR1 agonists

AbbVie initiates phase I study of SC-006 in patients with colorectal cancer

FDA approves Austedo to treat chorea associated with Huntington's disease

BMS presents isoform-selective Nav1.7 inhibitors with improved physicochemical properties

Keystone Nano initiates phase I trial of ceramide nanoliposome in advanced cancer

Merrimack completes Ipsen transaction, focuses on streamlined oncology pipeline

Roche and collaborators patent anti-influenza compounds

Androgen receptor antagonist TRC-253 enters phase I/II study in mCRPC

FDA clears Audentes Therapeutics' IND for AT-132

Galapagos to study filgotinib in Sjogren's syndrome, ankylosing spondylitis and psoriatic arthritis

XBiotech provides topline data from phase I/II study of antibody for S. aureus infections

Paratek reports promising topline data from phase III OPTIC study of omadacycline in CABP

Verona Pharma initiates phase IIa trial evaluating RPL-554 for cystic fibrosis

JCR initiates phase I/II study of JR-141 for Hunter's syndrome

Novel PRMT5 inhibitor JNJ-64619178 shows activity in lung cancer model

Sucampo Pharmaceuticals acquires Vtesse

LY-3200882, a novel high-selective TGFBR1 inhibitor for the treatment of cancer

Jazz Pharmaceuticals completes rolling submission of Vyxeos NDA

Intrexon, Ziopharm and Merck KGaA give update on CAR-T collaboration

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 9, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...